Annual EBIT
-$350.06 M
-$110.64 M-46.21%
December 31, 2023
Summary
- As of February 12, 2025, RXRX annual earnings before interest & taxes is -$350.06 million, with the most recent change of -$110.64 million (-46.21%) on December 31, 2023.
- During the last 3 years, RXRX annual EBIT has fallen by -$264.41 million (-308.73%).
- RXRX annual EBIT is now -471.58% below its all-time high of -$61.24 million, reached on December 31, 2019.
Performance
RXRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$95.12 M
+$2.55 M+2.61%
September 30, 2024
Summary
- As of February 12, 2025, RXRX quarterly earnings before interest & taxes is -$95.12 million, with the most recent change of +$2.55 million (+2.61%) on September 30, 2024.
- Over the past year, RXRX quarterly EBIT has dropped by -$2.99 million (-3.25%).
- RXRX quarterly EBIT is now -424.87% below its all-time high of -$18.12 million, reached on March 31, 2020.
Performance
RXRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$381.95 M
-$2.13 M-0.56%
September 30, 2024
Summary
- As of February 12, 2025, RXRX TTM earnings before interest & taxes is -$381.95 million, with the most recent change of -$2.13 million (-0.56%) on September 30, 2024.
- Over the past year, RXRX TTM EBIT has dropped by -$23.10 million (-6.44%).
- RXRX TTM EBIT is now -2007.57% below its all-time high of -$18.12 million, reached on March 31, 2020.
Performance
RXRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
RXRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.2% | -3.3% | -6.4% |
| 3 y3 years | -308.7% | -65.5% | -59.5% |
| 5 y5 years | -471.6% | -65.5% | -59.5% |
RXRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -90.7% | at low | -70.0% | +2.6% | -108.1% | at low |
| 5 y | 5-year | -471.6% | at low | -424.9% | +2.6% | -2007.6% | at low |
| alltime | all time | -471.6% | at low | -424.9% | +2.6% | -2007.6% | at low |
Recursion Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$95.12 M(-2.6%) | -$381.95 M(+0.6%) |
| Jun 2024 | - | -$97.67 M(+6.0%) | -$379.82 M(+5.8%) |
| Mar 2024 | - | -$92.13 M(-5.0%) | -$358.86 M(+8.1%) |
| Dec 2023 | -$350.06 M(+46.2%) | -$97.03 M(+4.3%) | -$332.03 M(+13.5%) |
| Sep 2023 | - | -$92.99 M(+21.2%) | -$292.48 M(+12.5%) |
| Jun 2023 | - | -$76.70 M(+17.4%) | -$259.92 M(+4.5%) |
| Mar 2023 | - | -$65.31 M(+13.6%) | -$248.76 M(+3.9%) |
| Dec 2022 | -$239.42 M | -$57.48 M(-4.9%) | -$239.42 M(-3.0%) |
| Sep 2022 | - | -$60.43 M(-7.8%) | -$246.90 M(+5.7%) |
| Jun 2022 | - | -$65.55 M(+17.1%) | -$233.67 M(+11.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$55.97 M(-13.8%) | -$209.03 M(+13.9%) |
| Dec 2021 | -$183.53 M(+114.3%) | -$64.95 M(+37.6%) | -$183.53 M(+27.4%) |
| Sep 2021 | - | -$47.21 M(+15.4%) | -$144.11 M(+19.7%) |
| Jun 2021 | - | -$40.90 M(+34.2%) | -$120.38 M(+22.8%) |
| Mar 2021 | - | -$30.47 M(+19.3%) | -$97.99 M(+14.4%) |
| Dec 2020 | -$85.65 M(+39.8%) | - | - |
| Dec 2020 | - | -$25.54 M(+8.8%) | -$85.65 M(+42.5%) |
| Sep 2020 | - | -$23.47 M(+26.8%) | -$60.11 M(+64.1%) |
| Jun 2020 | - | -$18.52 M(+2.2%) | -$36.64 M(+102.2%) |
| Mar 2020 | - | -$18.12 M | -$18.12 M |
| Dec 2019 | -$61.24 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual EBIT year-on-year change?
- What is Recursion Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly EBIT year-on-year change?
- What is Recursion Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM EBIT year-on-year change?
What is Recursion Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of RXRX is -$350.06 M
What is the all time high annual EBIT for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual earnings before interest & taxes is -$61.24 M
What is Recursion Pharmaceuticals annual EBIT year-on-year change?
Over the past year, RXRX annual earnings before interest & taxes has changed by -$110.64 M (-46.21%)
What is Recursion Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of RXRX is -$95.12 M
What is the all time high quarterly EBIT for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly earnings before interest & taxes is -$18.12 M
What is Recursion Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, RXRX quarterly earnings before interest & taxes has changed by -$2.99 M (-3.25%)
What is Recursion Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of RXRX is -$381.95 M
What is the all time high TTM EBIT for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM earnings before interest & taxes is -$18.12 M
What is Recursion Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, RXRX TTM earnings before interest & taxes has changed by -$23.10 M (-6.44%)